首页 / 院系成果 / 成果详情页

Changes in liver stiffness and its associated factors during oral antiviral therapy in Chinese patients with chronic hepatitis B  期刊论文  

  • 编号:
    8541cb23-8d1a-45c3-a5f5-d011ffc5a279
  • 作者:
    Li, Xu(李旭)#[1]Jin, Qinglong(金清龙)[1]Zhang, Hong(张洪)[2]Jing, Xue[3];Ding, Zhongyang[1];Zhou, Hongjie[1];Zhang, Zetian[1];Yan, Dongqing[1];Li, Dongmei[1];Gao, Pujun(高普均)*[1]Niu, Junqi(牛俊奇)*[1]
  • 语种:
    英文
  • 期刊:
    EXPERIMENTAL AND THERAPEUTIC MEDICINE ISSN:1792-0981 2017 年 13 卷 3 期 (1169 - 1175) ; MAR
  • 收录:
  • 关键词:
  • 摘要:

    The present study aimed to assess improvements in liver stiffness determined by transient elastography and associated factors in Chinese patients with chronic hepatitis B (CHB) during long-term treatment with oral antiviral drugs. A total of 334 consecutive Chinese patients with CHB who underwent oral antiviral therapy and received at least two liver stiffness measurements (LSMs) at the First Hospital of Jilin University (Changchun, China) from December 2012 to February 2015 were enrolled in the present study. The cohort included 201 patients without liver cirrhosis (group 0) and 133 patients with liver cirrhosis (group 1). Each patient was subjected to LSM twice with an interval of 6 months. The mean initial liver stiffness values were 14.01 +/- 9.37 and 21.59 +/- 10.25 kPa for patients in group 0 and group 1, respectively (P< 0.001). Multivariate analysis revealed that higher aspartate aminotransferase and lower alanine aminotransferase levels at baseline as well as higher alpha-fetoprotein levels at follow-up (24 weeks) were associated with a greater decline of liver stiffness in group 0. Furthermore, a higher liver stiffness at baseline and a longer course of antiviral therapy prior to the initial LSM were significantly correlated with a reduction of liver stiffness, whereas higher total bilirubin levels at follow-up contributed to increased liver stiffness in group 1. In conclusion, LSM at the beginning and the end of a 24-week observation period showed that antiviral drug therapy significantly improved in group 1, while a marked decreasing trend was also observed in group 0. In group 0, the reduction of liver stiffness was correlated with liver inflammation, whereas in group 1, it was correlated with the treatment duration prior to the initial LSM and serum levels of hepatitis B virus DNA. Furthermore, a higher liver stiffness at baseline was associated with a greater reduction of liver stiffness in each group.

  • 推荐引用方式
    GB/T 7714:
    Li Xu,Jin Qinglong,Zhang Hong, et al. Changes in liver stiffness and its associated factors during oral antiviral therapy in Chinese patients with chronic hepatitis B [J].EXPERIMENTAL AND THERAPEUTIC MEDICINE,2017,13(3):1169-1175.
  • APA:
    Li Xu,Jin Qinglong,Zhang Hong,Jing Xue,&Niu Junqi.(2017).Changes in liver stiffness and its associated factors during oral antiviral therapy in Chinese patients with chronic hepatitis B .EXPERIMENTAL AND THERAPEUTIC MEDICINE,13(3):1169-1175.
  • MLA:
    Li Xu, et al. "Changes in liver stiffness and its associated factors during oral antiviral therapy in Chinese patients with chronic hepatitis B" .EXPERIMENTAL AND THERAPEUTIC MEDICINE 13,3(2017):1169-1175.
  • 条目包含文件:
    文件类型:PDF,文件大小:
    正在加载全文
浏览次数:14 下载次数:0
浏览次数:14
下载次数:0
打印次数:0
浏览器支持: Google Chrome   火狐   360浏览器极速模式(8.0+极速模式) 
返回顶部